Young Survivors at Kantonsspital Aarau, Switzerland

Overview

The Young Survivors at Kantonsspital Aarau project assesses the prevalence and severity of late effects in survivors of childhood and adolescent cancer according to the modified CTCAE criteria prospectively. The clinical data are generated during regular follow-up care visits, the collection starts directly after completion of treatment and is longitudinally.

Full Title of Study: “Young Survivors at Kantonsspital Aarau, Switzerland – A Standardized Assessment of Long-Term and Late-Onset Health Events in Survivors of Childhood and Adolescent Cancer”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: March 15, 2071

Detailed Description

Background: Around 250-300 children and adolescents below the age of 21 years are newly diagnosed with cancer in Switzerland every year. Research led to remarkable progress in survival in the last decades. The 10-year survival rate in Switzerland is currently 87%. Previous research showed that, depending on the treatment exposure, a high proportion of these survivors suffer from chronic medical conditions, so called late effects. Many studies on late effects in former childhood cancer patients are based on retrospective data. However, this type of study design has unavoidable limitations, such as missing data, different coding and grading of severity of late effects, and the assessment at different time points. Therefore, we need prospectively collected data, including severity coding in a standardized way, to overcome these limitations. Objectives: The overarching aim of "Young Survivors at Kantonsspital Aarau, Switzerland" is to assess late effects in childhood cancer survivors prospectively and in a standardized way. These data will contribute to the increasing knowledge on long-term outcomes and late effects in the future. This new knowledge is important in order to be able to adapt and improve long-term follow-up care. In the longer term, survivors will benefit from this extensive and prospective data collection. Methods: "Young Survivors at Kantonsspital Aarau" has a registry-like design. Data produced during regular follow-up visits are collected in a comprehensive database and in a standardized way. We collect all information generated prospectively from start of the study onwards and retrospectively until January 2016. From 2016 onward, all medical records are kept electronically. We classify and grade the severity of late effects according to the modified National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.03). The outcome variables correspond to results from risk-stratified organ examinations, which are performed according to the Children's Oncology Group guidelines v5.0. The exposure variables correspond to information from the patients' medical history, including detailed information on cancer diagnosis and treatment. The data will be analyzed in an exposure- or organ system-driven approach. We start recruitment with patients diagnosed and treated at the Kantonsspital Aarau. The design of the study allows the inclusion of other clinics in the future. Research and significance: Research on late effects of former childhood cancer patients often relies on retrospective data collection, which is associated with unpreventable limitations. "Young Survivors at Kantonsspital Aarau" overcomes these limitations and additionally grades the severity of late effects in a standardized way. This allows us to analyze changes in severity of late effects over time, within and between survivors. This information will increase our knowledge on late effects and contribute to long-term follow-up care.

Interventions

  • Other: Physical examination, diagnostic tests, laboratory tests
    • Physical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
  • Other: Personal history
    • Personal history on diagnosis, treatment, and socioeconomic factors

Arms, Groups and Cohorts

  • Group A (largest part of the cohort)
    • Children, adolescents, and adults who are still in follow-up care (data are collected retrospectively until 2016 at the most)
  • Group B (very small part of the cohort)
    • Children, adolescents, and adults who left follow-up care (data are collected retrospectively until 2016 at the most)

Clinical Trial Outcome Measures

Primary Measures

  • Test results to assess organ-specific late effects (example of cardiac health)
    • Time Frame: at recruitment or 2016 onwards, whichever comes first
    • Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction when at risk for cardiac late effects

Secondary Measures

  • Test results to assess organ-specific late effects (example of cardiac health)
    • Time Frame: annually from recruitment or 2016 onwards, whichever comes first
    • Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction etc. when at risk for cardiac late effects
  • Sociodemographic and socioeconomic characteristics (e.g. age at clinical examination, gender, education or working situation, living situation)
    • Time Frame: annually from recruitment or 2016 onwards, whichever comes first
  • Comorbidities (e.g. arterial hypertension, obesity) as risk factors for late effects
    • Time Frame: annually from recruitment or 2016 onwards, whichever comes first
  • Diagnosis-related data (e.g. age at diagnosis, diagnosis, disease stage, treatment protocol)
    • Time Frame: at recruitment or 2016 onwards, whichever comes first
  • Treatment-related data (e.g. cumulative doses of chemotherapy and radiotherapy, surgery, hematopoietic stem cell transplantation )
    • Time Frame: at recruitment or 2016 onwards, whichever comes first

Participating in This Clinical Trial

Inclusion Criteria

Group A: Children and adolescents who:

  • have been treated for cancer in the Division of Oncology-Hematology, Department of Pediatrics, at the Kantonsspital Aarau, – have been diagnosed at age 0-18 years, – are still in regular follow-up care at the Kantonsspital Aarau, – have finished cancer treatment and entered follow-up care, and – signed informed consent Group B: Adolescents and adults who: – fulfill the same inclusion criteria as Group A – are not in regular follow-up care anymore Exclusion Criteria:

Childhood Cancer Survivors who:

  • are in a palliative situation or – have not given consent for further use of medical data

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kantonsspital Aarau
  • Provider of Information About this Clinical Study
    • Principal Investigator: Katrin Scheinemann, Division Head of Pediatric Oncology-Hematology – Kantonsspital Aarau
  • Overall Contact(s)
    • Katrin Scheinemann, MD, +41628384909, katrin.scheinemann@ksa.ch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.